ACPU
FOLD

Arrowgrass Capital Partners (US)’s Amicus Therapeutics FOLD Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-572,000
Closed -$2.84M – 595
2016
Q4 		$2.84M Buy
+572,000
New +$3.96M 0.03% 321
2015
Q3 		– Sell
-598,064
Closed -$8.46M – 480
2015
Q2 		$8.46M Buy
+598,064
New +$7.19M 0.13% 154

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s FOLD Position: Q1 2017 in Review

Arrowgrass Capital Partners (US) sold out of Amicus Therapeutics (FOLD) in Q1 2017, closing a stake of 572,000 shares — an estimated $2.84M sold.

Arrowgrass Capital Partners (US) first reported a position in FOLD in Q2 2015 and held it in 2 quarters. The position peaked at $8.46M in Q2 2015. 134 funds tracked by Wall St. Rank hold FOLD as of Q1 2017.

  • Arrowgrass Capital Partners (US) reported no remaining Amicus Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 572,000 Amicus Therapeutics shares in Q1 2017, an estimated $2.84M.
  • Arrowgrass Capital Partners (US) first reported a position in Amicus Therapeutics in Q2 2015 and held it in 2 quarters.
  • Arrowgrass Capital Partners (US)'s Amicus Therapeutics position peaked at $8.46M in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2017.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2017, filed 15 May 2017.